Unfortunately for some polycythemia vera (PV) patients, current treatment options may not be fully effective or well-tolerated and may cause serious side effects. But a promising investigational treatment is currently being clinically evaluated. Rusfertide, also known as PTG-300, is an investigational new drug designed to slow the release of iron into the bone marrow. The […]
MPN Specialist Explains PTG-300 and Clinical Trial for PV Patients
by David Wallace Hepcidin Mimetic PTG-300 Promising Treatment for PV How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV? How does iron deficiency play a role in polycythemia vera? What are the goals of this treatment? Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
